Share Name Share Symbol Market Type Share ISIN Share Description
Vernalis LSE:VER London Ordinary Share GB00B3Y5L754 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.125p -0.56% 22.00p 21.00p 21.75p 22.00p 21.25p 21.25p 378,927.00 09:39:32
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 12.0 -15.3 -3.2 - 115.76

Vernalis Share Discussion Threads

Showing 3301 to 3323 of 3325 messages
Chat Pages: 133  132  131  130  129  128  127  126  125  124  123  122  Older
DateSubjectAuthorDiscuss
22/4/2017
06:52
Not a pharmacokinetic or formulation issue? Did they mention labeling? If it was something simple then why not say so. Was it a safety issue? Why not say if it was or was not? Investors have the right to be kept fully informed. The FDA are serious people-don't issue complete response letters wily-nily. Are other products with similar profiles going to be similarly challenged? Can cost millions and take years to challenge the FDA or get them round to your way of thinking. RNS too vague to be sure this is not finished imo, and if Tuzistra sales don't start taking off Ver could be in in deep trouble imo. Also lack of news on Moxtag a concern imo for investors. Having started with huge cash pile this could easily be frittered away given costs of running an expensive mgmt team, sales force, regulatory hurdles etc. Without serious good news on sales, deals, approvals etc today's share price could look expensive before the year is out. imo
cumnor
22/4/2017
01:46
Vernalis is not getting product approval anytime soon. The 'delay' is due to their development partner and contract manufacturer Tris Pharma having an unsuccessful FDA inspection. This has put all development data into question along with the production of the registration batches. Tris has been told by the FDA that they are moving forward with a warning letter, which will put all product approvals on Hold from that facility for at least a year. Vernalis is screwed - should have picked a better business partner than Tris PHarma. Sell now....
jneubig
21/4/2017
09:10
Let's wait for a fuller explanation of what the FDA want.If it's just a labelling detail, then just a short delay. If they are after further data which requires testing then VER could miss the tight time schedule to be ready for next season.We should get more clarity once the FDA letter has been studied.
fhmktg
21/4/2017
08:39
'Delay' seems over reaction, not 'failed'........
chrisdgb
18/4/2017
08:57
PDUFA for ts- 07 Thursday.More ammunition!Please get Moxatag supply resolved asap,then the sales team can really get cracking.
fhmktg
30/3/2017
10:03
Remember the pattern last year was that only about 16% sales occurred prior to end December, the rest after. The June update should be a huge improvement on prescriptions and revenue and answer a lot of questions that the H1 figures couldn't. I have to say I was not overly impressed by the CEO on the conference call, and even less so by his unjustifiably massive pay packet. The CFO though seems clued up. I didn't like how they were so keen to play down the severity of the flu season this year and while it was only slightly up on 2015 prior to Dec the extent and severity of flu across the US after Christmas 2016 was massively up on the prior year. That is why H2 figures will be so revealing. Make no mistake if T-XR isn't heavily prescribed during a severe season like that then it never will be. We are ideally hoping for a Moxatag update asap, the longer that issue goes on the less likely a satisfactory resolution will be found. The ideal solution here is for the new contract pharma manufacturer taking over the old Suir site to take on production but Moxatag needs to be as cheap as possible (at least under $20) to justify it's use over ultra cheap (but multi dose) alternatives like standard Amoxicillin. The key will be ensuring it can be produced cost effectively enough to be a valid sell for patients where compliance is a major concern. Personally I was always sceptical about Moxatag, I'm not sure it's the right product for Vernalis to be selling and I think they paid far too much for the US rights. Perhaps I have misunderstood the product but I believe the drugs only benefit is that it can be taken once a day versus twice a day straight Amoxicillin but costs considerably more. I'm have much more faith in the cough cold products simply based on the massive market available there.
romeike
30/3/2017
09:26
Indeed, just thinking yesterday that a firm base had been established...let us hope the sales team are selling.!
chrisdgb
30/3/2017
09:24
Slow and steady rise from the double bottom of early March.Hope the June update confirms.Could do with a firm answer on Moxatag
fhmktg
29/3/2017
12:30
Nice sustained buys this morning!Not day traders?
fhmktg
20/3/2017
13:25
@buywell3 What do you want, a medal? June results, revenue from T XR and position on Moxatag, will decide this company's fate.
romeike
15/3/2017
11:13
Big note out from Edison today, they seem to have moved back over 80p DCF value..........
chrisdgb
14/3/2017
22:53
I see this has dropped over 10p further since I posted buywell3 2 Nov '16 - 05:15 - 1489 of 1574 0 0 Edit Do you guys realize that not all drugs that get FDA approval go on to sell in a way that makes the parent company any lolly ?
buywell3
14/3/2017
21:45
updated the 3 day chart in the header to a 10 day chart which I think is more useful to see recent prices
bountyhunter
08/3/2017
18:24
i thought so too. :-)
novandi
07/3/2017
19:53
thanks for posting novandi - an interesting and comprehensive read - I've added the link to the end of the header
bountyhunter
07/3/2017
19:31
interesting read for those interested in VER: hxxps://www.simpvestor.com/plcprofiles/2017/2/25/vernalis
novandi
07/3/2017
11:23
Market currently obsessed with central bank manoeuvres and nothing else, positive news released elsewhere e.g. GSK also largely being ignored.
romeike
06/3/2017
17:11
that's what I was thinking, doesn't make a lot of sense really!
bountyhunter
06/3/2017
17:02
News of €2 million upfront payment from Servier largely ignored today
romeike
06/3/2017
11:57
Somebody is building a stake, 400k bought this morning.
fhmktg
01/3/2017
10:55
Unfortunately thin news flow until June may not provide the necessary interest needed to improve the share price beyond pre-update levels but there is the possibility of early resolution to the moxatag supply issue and further research milestones. Most other news expected H2.
romeike
28/2/2017
16:22
Chunky buying today.
fhmktg
24/2/2017
15:49
And continuing!
fhmktg
Chat Pages: 133  132  131  130  129  128  127  126  125  124  123  122  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20170424 09:34:49